“We're reiterating our full-year revenue and EPS guidance today and both our revenue and EPS growth will accelerate in the fourth quarter.”

In context

“zation remains extremely focused on improving our margins over time. We're also prioritizing investments in our pipeline and important product launch capabilities, like hiring 100s of mappers to support PFA growth and market development specialists in renal denervation to accelerate Ardian growth. At the same time, we're returning significant capital to our shareholders, primarily through our strong and growing dividend and from time-to-time, opportunistic share repurchases. Regarding our portfolio, we've increased our focus on finding tuck-in acquisitions that can enhance our growth and margin profile. We're also continuing to actively evaluate our portfolio at the business, product line, and geographic level, all through the lens of maximizing shareholder value. Now turning to guidance. We're reiterating our full-year revenue and EPS guidance today and both our revenue and EPS growth will accelerate in the fourth quarter. On the top line, we continue to expect FY ‘25 organic revenue growth to be in the range of 4.75 to 5%. For Q4, given the strong trajectory of our growth drivers and expected acceleration in the cardiovascular portfolio, we're comfortable with current street organic revenue growth consensus and expect to deliver our 10th quarter in a row of mid-single-digit revenue growth. Based on recent rates, FX would have an impact to fiscal ‘25 in the range of $275 million to $325 million, including $125 million to $175 million in the fourth quarter. On the bottom line, we continue to expect fiscal ‘25 non-GAAP diluted EPS in the range of $5.44 to $5.50 and are comfortable with current full-year street consensus. Based on recent rates, our EPS guide factors in a five-point impact from foreign currency”